KYMR
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Kymera Therapeutics, Inc. (KYMR) is rated C+ (2.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (A+); its weakest is Growth (F).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-13 | C (2.3) | F (0.6) | C- (1.9) | B+ (3.5) | A+ (5.0) | C+ (2.7) |
| 2026-11-06 | C (2.4) | F (0.6) | C- (1.9) | B+ (3.8) | A+ (5.0) | C+ (2.7) |
| 2026-10-30 | C (2.4) | C- (2.1) | C (2.3) | B+ (3.8) | A+ (5.0) | B- (3.1) |
| 2026-10-23 | C (2.5) | C- (2.1) | C (2.3) | B (3.3) | A+ (5.0) | B- (3.0) |
| 2026-10-16 | C (2.5) | C- (2.0) | C (2.3) | B (3.2) | A+ (5.0) | B- (3.0) |